GleamWall
中文EN

AYTU AYTU BIOPHARMA, INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1385818 · Fiscal year ends 06/30

Financial factors as of 2026-09-30 (2027Q1), TTM = sum of the last four quarters

Growth

TTM revenue YoY-8.1%
TTM net income YoY-53.8%
TTM EPS YoY-55.0%
Revenue 3-yr CAGR-15.7%
Net income 3-yr CAGR—

Margins

Gross margin63.3%
Operating margin-18.4%
Net margin-34.3%
FCF margin—
EBITDA margin-14.2%

Returns

ROE-73.4%
ROA-17.9%
ROIC (approx.)-87.4%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets68.2%
Debt / equity0.33x
Current ratio1.07x
Interest coverage-6.01x

Cash quality & payout

Operating cash flow / net income-0.18x
Accruals ratio-21.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q12026-09-302026Q4*2026-06-302026Q32026-03-312026Q22025-12-312026Q12025-09-302025Q4*2025-06-302025Q32025-03-312025Q22024-12-31
Income statement
Revenue$14.84M$16.11M$12.41M$15.16M$13.89M$15.13M$18.45M$16.22M
Cost of revenue$5.41M$5.70M$4.81M$5.54M$4.70M$4.88M$5.65M$5.43M
Gross profit$9.44M$10.41M$7.60M$9.62M$9.19M$10.25M$12.81M$10.79M
R&D expense—$0$0$0$0$216,000$162,000$522,000
SG&A expense$5.99M$4.30M$4.97M$5.07M$4.92M$3.70M$4.11M$4.45M
Operating income-$3.93M-$777,000-$4.06M-$1.97M-$1.50M-$7.62M$2.42M-$1.70M
Interest expense$408,000$383,000$436,000$560,000$516,000$730,000$900,000$1.08M
Pretax income-$3.88M-$4,000-$5.61M-$10.58M$1.97M-$19.44M$3.82M$382,000
Income tax$0$11,000$10,000$0$0$437,000-$122,000-$283,000
Net income-$3.88M-$15,000-$5.62M-$10.58M$1.97M-$19.82M$3.99M$788,000
EBITDA-$2.81M$344,000-$3.96M-$1.87M-$701,000-$6.16M$2.52M-$1.59M
EPS (basic)-0.20—-0.53-1.050.21—0.650.13
EPS (diluted)-0.20—-0.53-1.05-0.08—0.21-0.26
Weighted avg. shares (diluted)19.33M—10.51M10.04M19.48M—8.20M8.49M
Balance sheet
Cash & equivalents$25.49M$26.31M$26.71M$30.02M$32.63M$30.95M$18.17M$20.40M
Receivables$20.33M$22.78M$24.49M$30.92M$33.23M$31.16M$35.83M$25.40M
Inventory$6.02M$6.86M$7.46M$8.66M$10.10M$11.43M$11.06M$11.09M
Current assets$57.16M$61.76M$67.33M$76.24M$81.11M$79.18M$72.51M—
PP&E, net$353,000$385,000$407,000$484,000$500,000$532,000$546,000$516,000
Intangibles$40.32M$41.40M$42.49M$43.58M$41.43M$42.20M$48.71M$49.96M
Total assets$99.17M$105.01M$111.69M$122.00M$124.99M$124.18M$124.20M$116.23M
Current liabilities$53.33M$54.66M$59.97M$65.56M$65.99M$63.06M$70.71M$64.05M
Short-term debt$1.86M$1.86M$1.86M$1.86M$1.86M$1.86M$1.86M$1.86M
Long-term debt$8.65M$9.10M$9.55M$10.00M$10.45M$10.89M$9.54M$9.98M
Total debt$10.51M$10.96M$11.41M$11.86M$12.30M$12.75M$11.39M$11.84M
Total liabilities$67.61M$69.73M$76.55M$107.80M$101.82M$105.21M$89.30M$85.46M
Shareholders' equity$31.56M$35.27M$35.14M$14.20M$23.17M$18.97M$34.90M$30.77M
Net debt-$14.98M-$15.35M-$15.31M-$18.17M-$20.33M-$18.20M-$6.78M-$8.56M
Shares outstanding10.87M10.73M10.73M10.73M9.91M8.98M6.17M6.17M
Cash flow statement
Operating cash flow-$275,000$4.41M-$4.18M$3.67M-$618,000$2.80M-$6.46M$2.90M
Capital expenditure—$12,000$0$17,000$0$17,000$69,000$6,000
Free cash flow—$4.39M-$4.18M$3.66M-$618,000$2.79M-$6.52M$2.90M
Investing cash flow—-$12,000$0-$17,000$0-$3.02M-$69,000$145,000
Financing cash flow-$539,000-$4.80M$872,000-$6.26M$2.30M$12.99M$4.30M-$2.76M
Depreciation & amortization$1.12M$1.12M$100,000$100,000$803,000$1.46M$100,000$100,000
Stock-based compensation$171,000$146,000$148,000$283,000$114,000$113,000$139,000$151,000

Free plan shows the latest 8 periods; Pro shows all 69 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.